BioViva’s aims to be an advanced medicinal product access platform. To this end BioViva is committed to the following:

  • Bridging stakeholders with biotechnology

  • Accelerated path  to human trials

  • Growing knowledge base

  • Ensuring dependability

 

BioViva is a platform to expedite the development of drugs and treatments that affect human healthspan. To achieve this goal BioViva has developed a comprehensive set of biomarkers of aging, which include molecular, physiological, anatomical, clinical, and qualitative markers. BioViva also collaborates with clinicians, biomedical scientists, and statisticians to develop innovative protocols for adaptive clinical trials for gene and cells therapies. Finally, BioViva has built a bioinformatics pipeline to analyze the data generated from the biomarkers of aging in human trials and validate the treatments that are effective for treating the aging process.

BioViva has recently partnered with a patient-paid-for clinical trial company Integrated Health Systems (IHS). IHS connects doctors with patients who want to take part in paid-for clinical trials. During our collaboration with IHS, they will utilize our adaptive clinical trial protocols to conduct gene and cell therapy trials. All patients will undergo pre- and post-testing using BioViva’s comprehensive biomarkers of aging platform. Treatment efficacy and patient well being will be assessed using our bioinformatics pipeline.

The goal of BioViva is to accelerate the development of products that will effectively, and cost-efficiently treat biological aging. Our platform is designed to provide expedited and reliable feedback to our clinical and manufacturing partners, so that they may rapidly iterate their products and services to help patients improve the quality and quantity of life.

Success for BioViva entails finding therapies that work quantitatively by reversing or slowing biological aging in humans as measured by DNA methylation, metabolic, physiological, anatomical, and clinical markers. In addition, we will qualitatively improve patient well-being by helping them achieve an optimally healthy life.

BioViva is a platform for anti-aging biotech development. BioViva is to biotech, what meta-analysis is to medical research. BioViva’s platform is designed to accommodate all forms of research and development that target the aging process in humans. We work with biotech companies and biologic manufacturers and help them conduct accelerated adaptive clinical trials to ascertain the efficacy of their products in treating the aging process.

According to FDA drug approvals between 2004 and 2014, there is a 15 percent chance of going from Phase 1 through to FDA approvals for biologics, and a 7 percent chance of success for small molecules. This high rate of failure highlights the problems with preliminary drug testing platform. BioViva is a cost-effective solution for biotech companies to rapidly test their drugs in humans to determine where to embark on the expensive and time-consuming FDA or EMA approval process.

The biggest challenge in evaluating the efficacy of anti-aging treatments are biomarkers of aging. Currently, our the best biomarkers of aging are loosely associated with biological aging especially in people aged over 50.

This is clearly the biggest problem as we cannot wait for 10 years to test every treatment. Therefore at BioViva, we have designed a comprehensive biomarker of aging platform that should be able to ascertain anti-aging treatment efficacy within a couple of years.

 

In summary, we want to help humans live long and healthy lives, and we have built a platform to assess anyone's products that can help us achieve that goal.

BioViva’s aims to be an advanced medicinal product access platform. To this end BioViva is committed to the following:

 

  • Bridging stakeholders with biotechnology

  • Accelerated path  to human trials

  • Growing knowledge base

  • Ensuring dependability

 

BioViva is a platform to expedite the development of drugs and treatments that affect human healthspan. To achieve this goal BioViva has developed a comprehensive set of biomarkers of aging, which include molecular, physiological, anatomical, clinical, and qualitative markers. BioViva also collaborates with clinicians, biomedical scientists, and statisticians to develop innovative protocols for adaptive clinical trials for gene and cells therapies. Finally, BioViva has built a bioinformatics pipeline to analyze the data generated from the biomarkers of aging in human trials and validate the treatments that are effective for treating the aging process.

BioViva has recently partnered with a patient-paid-for clinical trial company Integrated Health Systems (IHS). IHS connects doctors with patients who want to take part in paid-for clinical trials. During our collaboration with IHS, they will utilize our adaptive clinical trial protocols to conduct gene and cell therapy trials. All patients will undergo pre- and post-testing using BioViva’s comprehensive biomarkers of aging platform. Treatment efficacy and patient well being will be assessed using our bioinformatics pipeline.

The goal of BioViva is to accelerate the development of products that will effectively, and cost-efficiently treat biological aging. Our platform is designed to provide expedited and reliable feedback to our clinical and manufacturing partners, so that they may rapidly iterate their products and services to help patients improve the quality and quantity of life.

Success for BioViva entails finding therapies that work quantitatively by reversing or slowing biological aging in humans as measured by DNA methylation, metabolic, physiological, anatomical, and clinical markers. In addition, we will qualitatively improve patient well-being by helping them achieve an optimally healthy life.

BioViva is a platform for anti-aging biotech development. BioViva is to biotech, what meta-analysis is to medical research. BioViva’s platform is designed to accommodate all forms of research and development that target the aging process in humans. We work with biotech companies and biologic manufacturers and help them conduct accelerated adaptive clinical trials to ascertain the efficacy of their products in treating the aging process.

According to FDA drug approvals between 2004 and 2014, there is a 15 percent chance of going from Phase 1 through to FDA approvals for biologics, and a 7 percent chance of success for small molecules. This high rate of failure highlights the problems with preliminary drug testing platform. BioViva is a cost-effective solution for biotech companies to rapidly test their drugs in humans to determine where to embark on the expensive and time-consuming FDA or EMA approval process.

The biggest challenge in evaluating the efficacy of anti-aging treatments are biomarkers of aging. Currently, our the best biomarkers of aging are loosely associated with biological aging especially in people aged over 50.

This is clearly the biggest problem as we cannot wait for 10 years to test every treatment. Therefore at BioViva, we have designed a comprehensive biomarker of aging platform that should be able to ascertain anti-aging treatment efficacy within a couple of years.

 

In summary, we want to help humans live long and healthy lives, and we have built a platform to assess anyone's products that can help us achieve that goal.

Overexpression of genes to suppress dsRNA innate immunity

600px-Humanstemcell.jpg

BioViva scientist Ali Fallah et al have worked on the reprogramming potential of GCS (germline derived stem cells) the self-renewal capacity of which makes them a good source for research and clinical use, and shown that their innate immunity can be manipulated via overexpression of three key genes.

 

Source: NCBI Pub Med

Comment

Avi Roy

- PhD student researching Aging, Mitochondria, and Regenerative Medicine - I currently write for The Conversation (http://bit.ly/13WVyUW) and I have written for The Guardian (http://bit.ly/13WVtRh) - Ringleader of the Oxford University Scientific Society - Co-conspirator at the Oxford Transhumanism and Emerging Technologies - Designing exciting events with the British Science Association Oxford - Advisory Board member at Lifeboat Foundation's Life Extension Board, and the Sustainability Board - Also, I am an Ultimate (frisbee) enthusiast - Yes, unfortunately that's me trying to catch the frisbee

Gene Therapy using anti-inflammatory cytokines promising against MS

Astrocyte5.jpg

 BioViva scientist Ali Fallah and his team work on novel gene therapy using anti-inflammatory cytokines and show that these can be a promising approach against multiple sclerosis (MS). 

Source:  Cell Journal.

 

Comment

Avi Roy

- PhD student researching Aging, Mitochondria, and Regenerative Medicine - I currently write for The Conversation (http://bit.ly/13WVyUW) and I have written for The Guardian (http://bit.ly/13WVtRh) - Ringleader of the Oxford University Scientific Society - Co-conspirator at the Oxford Transhumanism and Emerging Technologies - Designing exciting events with the British Science Association Oxford - Advisory Board member at Lifeboat Foundation's Life Extension Board, and the Sustainability Board - Also, I am an Ultimate (frisbee) enthusiast - Yes, unfortunately that's me trying to catch the frisbee

Source of stem cells that are easily available and raise no ethical concerns

dna-1889084_1920.jpg

Research by BioViva scientist Ali Fallah: " In this study, we describe an efficient approach for stable knockdown of adenosine kinase (ADK) using lentiviral system, in an astrocytoma cell line and in human Wharton’s jelly mesenchymal stem cells (hWJMSCs). These sources of stem cells besides having multilineage differentiation potential and immunomodulatory activities, are easily available in unlimited numbers, do not raise ethical concerns and are attractive for gene manipulation and cell-based gene therapy."

Comment /Source

Avi Roy

- PhD student researching Aging, Mitochondria, and Regenerative Medicine - I currently write for The Conversation (http://bit.ly/13WVyUW) and I have written for The Guardian (http://bit.ly/13WVtRh) - Ringleader of the Oxford University Scientific Society - Co-conspirator at the Oxford Transhumanism and Emerging Technologies - Designing exciting events with the British Science Association Oxford - Advisory Board member at Lifeboat Foundation's Life Extension Board, and the Sustainability Board - Also, I am an Ultimate (frisbee) enthusiast - Yes, unfortunately that's me trying to catch the frisbee

BioViva Supports Patient Advocacy For Gene Therapy

 Alison Frase, with her son Joshua at age five in 2000, first learned about gene therapy more than 10 years ago. Sour

Alison Frase, with her son Joshua at age five in 2000, first learned about gene therapy more than 10 years ago. Sour

"Patient advocates are the driving force behind the development of many new drugs and amendments to medical regulations. It is the common man and woman who drive technology by demanding access to it. I know, because first and foremost, I am a patient advocate.

It is an absolute tragedy that Ms. Frase lost her son Joshua to X-linked myotubular myopathy. As a mother I cannot imagine anything more devastating. We all hope for a better tomorrow, but we need to realize that unless we act now, for many people, there will be no tomorrow. Each of us have a responsibility to accelerate medicine so that we can put an end to these horrible tragedies."

Liz Parrish, CEO BioViva, comments on Determined Parents are Moving the Needle on Gene Therapy

 

1 Comment

Avi Roy

- PhD student researching Aging, Mitochondria, and Regenerative Medicine - I currently write for The Conversation (http://bit.ly/13WVyUW) and I have written for The Guardian (http://bit.ly/13WVtRh) - Ringleader of the Oxford University Scientific Society - Co-conspirator at the Oxford Transhumanism and Emerging Technologies - Designing exciting events with the British Science Association Oxford - Advisory Board member at Lifeboat Foundation's Life Extension Board, and the Sustainability Board - Also, I am an Ultimate (frisbee) enthusiast - Yes, unfortunately that's me trying to catch the frisbee

Dual Gene Therapy Has Beneficial Effects On Blood Biomarkers And Muscle Composition

Dual Gene Therapy Has Beneficial Effects On Blood Biomarkers And Muscle Composition

In April 2016 BioViva USA Inc. published a press release stating that Elizabeth Parrish, CEO, had experienced telomere lengthening in her leukocytes, as a result of an injection of two experimental therapies. These consisted of a myostatin inhibitor to protect against loss of muscle mass with age, and a telomerase inducer to battle stem cell depletion responsible for diverse age-related diseases and infirmities.

Read More

One Year Anniversary Of Bioviva's Gene Therapy Against Human Aging

One Year Anniversary Of Bioviva's Gene Therapy Against Human Aging

It has officially been one year since I volunteered to take the first gene therapy to treat biological aging. It has been an amazing year! It began with a great deal of excitement in the weeks leading up to taking the treatment. The excitement of treatment day was followed by months of anticipation, while unfortunately we have not yet succeeded in undoing all aspects of aging just yet, we have gathered tantalizing human data for the first time in history. 

Read More

Bioviva, Gene Therapy And Blockchain Merges In Russia

Bioviva, Gene Therapy And Blockchain Merges In Russia

During June 20th to the 23rd, founder and CEO of BioViva USA Inc, Elizabeth Parrish visited Moscow at the invitation of board member of the Blockchain Community and founder of Future Fintech accelerator, Alex Fork.  As a result of the meeting an announcement was made with BioViva to open an outreach office in Russia. Additionally, an agreement to implement a crowd investing campaign for BioViva using the Waves Blockchain platform was made.

Read More

Bioviva Talks At The 2b Ahead Thinktank Future Congress In Germany

Bioviva Talks At The 2b Ahead Thinktank Future Congress In Germany

The 2b AHEAD ThinkTank Future Congress ranks as one of the most attractive events in the European innovation scene. For the last 15 years, 300 leading figures in business and society have gathered annually discuss the future of business, with guests including executive directors and CEOs, innovation managers, marketing leaders, extreme lead users, and innovative entrepreneurs. 2016’s annual congress was exclusively focused on future forecasts, speed and agility being a major driver of growth today.

Read More

Deep Knowledge Life Sciences And Bioviva Announce Partnership

Deep Knowledge Life Sciences And Bioviva Announce Partnership

“BioViva aims to make gene therapy affordable to everyone. Dmitry Kaminskiy, the founding partner of Deep Knowledge Life Sciences, is enthusiastically funding gene therapy, and is himself an early adopter”, said BioViva CEO Elizabeth Parrish, adding “We both want to see a world where investors actually live their legacy instead of just leaving it”, alluding to a possible future trend.

Read More

Alzheimer’s Cure

Alzheimer’s Cure

There are telomere lengthening compounds available right now for use in research labs. They are not currently available for human use. A group of scientists wants to test these compounds on aging humans now to see if the telomere lengthening effects will induce meaningful age reversal effects.

Telomeres in our cells shorten as we grow older and create cellular havoc that predisposes us to multiple age-related pathologies. These experimental enzymes promote telomere lengthening and in the process offer an intriguing opportunity to circumvent biological aging processes.

Read More

The Telomeres-P53-pgc Aging Axis

The Telomeres-P53-pgc Aging Axis

This 2011 paper by Dr DePinho builds on previous papers and his theory of the “telomere-p53-PGC axis”. This is a big reason along with the work of Dr Michael Fossel I believe telomerase therapy is probably the best chance of radical life extension in the near future. This is one of a number of papers that implicate dysfunctional telomeres in a cascade that causes mitochondrial dysfunction and various other aging consequences.

Read More